Atlas Trials

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

Clinical trial NCT04197479 · COMPLETED

Trial details

NCT number
NCT04197479
Sponsor
Madrigal Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Non-Alcoholic Fatty Liver Disease
Start date
2019-12-16
Primary completion
2023-01-06
Enrollment
1343

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.